Molecure announces management changes
Polish clinical-stage biotech Molecure (WSE: MOC) has announced that Dr Samson Fung, currently chief medical officer, has been appointed to the company’s management board.
Dr Adam Gołębiowski has stepped down from the management board to take on the role of senior research fellow at Molecure. In parallel, Dr Zbigniew Zasłona, has been promoted to chief scientific officer from his current position as vice president research biology. Dr Zasłona, will remain on Molecure’s management board.
These changes are designed to better position the company to rapidly progress its clinical stage assets towards meaningful endpoints and partnering transactions, while simultaneously developing its early-stage programs, including its innovative RNA discovery platform, to create a balanced pipeline of first-in-class assets with breakthrough therapy potential.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze